Eli Lilly’s weight-loss drug Mounjaro races to second spot in India’s pharma market

Eli Lilly’s diabetes and weight-loss drug Mounjaro has taken India’s pharma market by storm - rising to the second spot in sales within just six months of launch.

According to PharmaTrac data for September 2025, Mounjaro clocked ₹80 crore in monthly sales - just behind GSK’s Augmentin at ₹85 crore and ahead of Pan at ₹77 crore - marking a sharp 43% month-on-month jump.

Launched in mid-March, Mounjaro has already crossed ₹233 crore in cumulative sales, reshaping India’s ₹750-crore anti-obesity drug market.

In a country often dubbed the diabetes and obesity capital of the world, this rapid uptake signals a major lifestyle and public-health shift as millions turn to medication to manage weight and glucose levels.

Experts say Mounjaro’s success stems from its first-mover advantage and superior efficacy - showing 20–22% weight loss versus 16–18% for Novo Nordisk’s Wegovy.

Riding on this momentum, Eli Lilly has announced a $1 billion investment in India to expand contract manufacturing, strengthen local supply chains, and set up a global quality hub in Hyderabad, underscoring the company’s confidence in India as a key growth market for next-generation metabolic therapies.

With India’s ₹19,000-crore diabetes market offering huge headroom for innovation, Mounjaro’s record-breaking growth shows that the race for dominance in this space has only just begun.